Globally, now in the third year of the pandemic, COVID-19 deaths have exceeded more than 6 million. As new subvariants emerge and spread, vaccines work to limit the worst of COVID-19 and continue to be important. Restraints are lifted, and COVID-19 may be seen as done for some, but COVID-19 is not yet done with others, no matter how badly everyone wants it to end. The SARS- CoV-2 pandemic has caused considerable morbidity and mortality worldwide. The protection provided by vaccines and booster doses offer a method of mitigating severe clinical outcomes and mortality. As debates over additional booster shots for COVID-19 intensify, many researchers are looking to the universal coronavirus vaccine model as a guide for managing future variants of SARS-CoV-2 and preempt the next COVID-19 surge.
Covid-19|vaccines|pandemics|vaccination|health Inequities|pregnancy

Almost a year after the worldwide appearance of the coronavirus (SARS-CoV-2), several novel vaccines of diverse platforms have been successfully developed and administered. Two mRNA vaccines represented a new type of vaccine that comprised of synthetic mRNA molecules containing the code sequence necessary to build the SARS-CoV-2 spike protein. These mRNA vaccines almost single handedly carried the brunt of the US COVID-19 immunization strategy during the past three years. The known and potential benefits of COVID-19 vaccination outweigh the risks and adverse complications. The ongoing COVID-19 pandemic has stimulated unprecedented research on aspects of the vaccines’ ability to reduce the risk of severe infection and death. Likewise, basic immunological studies are pivotal to unraveling the potential and long-term effects of the vaccines as well as to be able to make adjustments to new vaccine development. As the circulating virus strain continues to evolve, updated vaccines will be critical to protecting the population, particularly the elderly and immune compromised.
COVID-19 ; Vaccination ; Post-Acute COVID-19 Syndrome ; Myocarditis